高端人才流动的轨迹,映射出跨国药企在中国战略调整的方向与决心。近日,默克中国发布两项重磅人事任命,罗杰仁重返中国担任默克中国总裁,该任命已于2026年2月1日正式生效。同时,穆安德正式出任默克中国医药健康业务董事总经理。此次调整中最引人注目的是周虹离开默克,加入诺和诺德担任全球产品与投资组合战略执行副总裁。周虹的离职与履新,成为近期跨国药企高管频繁变动中的标志性事件。默克中国管理层大调整默克中国...
Source Link高端人才流动的轨迹,映射出跨国药企在中国战略调整的方向与决心。近日,默克中国发布两项重磅人事任命,罗杰仁重返中国担任默克中国总裁,该任命已于2026年2月1日正式生效。同时,穆安德正式出任默克中国医药健康业务董事总经理。此次调整中最引人注目的是周虹离开默克,加入诺和诺德担任全球产品与投资组合战略执行副总裁。周虹的离职与履新,成为近期跨国药企高管频繁变动中的标志性事件。默克中国管理层大调整默克中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.